ZBIO Zenas Biopharma Inc.

Price (delayed)

$18.54

Market cap

$1.17B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$9.1

Enterprise value

$937.1M

?
Relative Growth: Rel. Growth: 10
Relative Strength: Rel. Strength: 35
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 0

We are a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need. With the evolving understanding of ...

Highlights
The quick ratio has soared by 114% from the previous quarter and by 84% YoY
Zenas Biopharma's equity has increased by 39% QoQ and by 18% YoY
ZBIO's EPS is up by 31% year-on-year but it is down by 8% since the previous quarter
Zenas Biopharma's net income has plunged by 161% YoY and by 13% from the previous quarter
The gross profit has dropped by 100% since the previous quarter and by 100% year-on-year

Key stats

What are the main financial stats of ZBIO

ZBIO stock price

How has the Zenas Biopharma stock price performed over time
Intraday
6.55%
1 week
-0.11%
1 month
-14.01%
1 year
94.14%
YTD
-48.94%
QTD
-5.17%

Financial performance

How have Zenas Biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$423.08M
Net income
-$425.15M
Gross margin
N/A
Net margin
N/A
Zenas Biopharma's net income has plunged by 161% YoY and by 13% from the previous quarter
The company's operating income has shrunk by 144% YoY and by 10% QoQ
The gross profit has dropped by 100% since the previous quarter and by 100% year-on-year
The revenue has plunged by 100% from the previous quarter and by 100% YoY

Price vs fundamentals

How does ZBIO's price correlate with its fundamentals

Growth

What is Zenas Biopharma's growth rate over time

Valuation

What is Zenas Biopharma stock price valuation
P/E
N/A
P/B
3.17
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ZBIO's EPS is up by 31% year-on-year but it is down by 8% since the previous quarter
Zenas Biopharma's equity has increased by 39% QoQ and by 18% YoY
The P/B is 34% less than the last 4 quarters average of 4.5
The revenue has plunged by 100% from the previous quarter and by 100% YoY

Efficiency

How efficient is Zenas Biopharma business performance
ZBIO's ROA has dropped by 96% year-on-year but it is up by 14% since the previous quarter
ZBIO's return on invested capital has surged by 85% year-on-year and by 29% since the previous quarter
The ROE has shrunk by 72% YoY and by 7% QoQ

Dividends

What is ZBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ZBIO.

Financial health

How did Zenas Biopharma financials performed over time
Zenas Biopharma's total assets is 82% more than its total liabilities
Zenas Biopharma's total liabilities has surged by 191% QoQ
Zenas Biopharma's total assets has soared by 124% YoY and by 95% from the previous quarter
ZBIO's debt is 21% smaller than its equity
Zenas Biopharma's equity has increased by 39% QoQ and by 18% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.